BTG plc (LON:BTG)‘s stock had its “buy” rating reaffirmed by stock analysts at Numis Securities Ltd in a report issued on Thursday. They presently have a GBX 900 ($11.94) target price on the stock. Numis Securities Ltd’s price objective suggests a potential upside of 26.23% from the company’s current price.

A number of other research firms also recently issued reports on BTG. Shore Capital restated a “not rated” rating on shares of BTG plc in a report on Thursday, July 13th. J P Morgan Chase & Co restated a “neutral” rating on shares of BTG plc in a report on Monday, September 18th. Stifel Nicolaus restated a “buy” rating and set a GBX 800 ($10.61) price objective on shares of BTG plc in a report on Wednesday, August 30th. Deutsche Bank AG restated a “buy” rating and set a GBX 775 ($10.28) price objective on shares of BTG plc in a report on Thursday, September 21st. Finally, Peel Hunt restated a “hold” rating and set a GBX 680 ($9.02) price objective on shares of BTG plc in a report on Wednesday, September 20th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. BTG plc currently has an average rating of “Buy” and a consensus price target of GBX 780.33 ($10.35).

BTG plc (LON BTG) opened at 713.00 on Thursday. The company has a 50-day moving average of GBX 682.42 and a 200-day moving average of GBX 662.79. BTG plc has a 52 week low of GBX 528.36 and a 52 week high of GBX 738.50. The firm’s market cap is GBX 2.75 billion.

COPYRIGHT VIOLATION WARNING: “BTG plc (BTG) Rating Reiterated by Numis Securities Ltd” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/10/07/btg-plc-btg-rating-reiterated-by-numis-securities-ltd.html.

About BTG plc

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.

Analyst Recommendations for BTG plc (LON:BTG)

Receive News & Stock Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related stocks with our FREE daily email newsletter.